Skip to main content

Business

Pharmaceutical Supply Agreement (Kenya)

A Kenya Pharmaceutical Supply Agreement under the Pharmacy and Poisons Act Cap. 244, governing the supply of medicines, medical devices, and pharmaceutical products between a manufacturer, distributor, or wholesaler and a pharmacy or healthcare facility in Kenya.

Key facts

KenyaKenyaEnglish (KE)FreePDF & Word
Legal basisPharmacy and Poisons Act Cap. 244Signature lines in this template: 2 parties
Pharmaceutical Supply Agreement

Medicine Supply Contract — Pharmacy and Poisons Act Cap. 244

Agreement Header

PHARMACEUTICAL SUPPLY AGREEMENT Made under the Pharmacy and Poisons Act Cap. 244 and the Competition Act No. 12 of 2010 BETWEEN: SUPPLIER: [Supplier Legal Name] Registration No.: [Supplier Company Registration Number] Address: [Supplier Physical Address] PPB Wholesale Dealer Licence No.: [Supplier PPB Wholesale Dealer Licence Number] KRA PIN: [Supplier KRA PIN] Superintendent Pharmacist: [Supplier Superintendent Pharmacist (Name and RPh No.)] (the Supplier) AND BUYER: [Buyer Legal Name] Address: [Buyer Physical Address] PPB Premises Registration No.: [Buyer PPB Premises Registration Number] KRA PIN: [Buyer KRA PIN] Superintendent Pharmacist: [Buyer Superintendent Pharmacist (Name and RPh No.)] (the Buyer)

Background and Regulatory Basis

BACKGROUND A. The Supplier is a duly licensed pharmaceutical wholesale drug dealer / manufacturer holding a valid licence from the Pharmacy and Poisons Board (PPB) under Section 32 of the Pharmacy and Poisons Act Cap. 244. B. The Buyer is a licensed pharmacy / healthcare facility holding a valid PPB registration certificate under Cap. 244. C. Both parties confirm that all products to be supplied under this agreement are registered with the PPB in the Kenya Register of Pharmaceutical Products under Section 35 of Cap. 244. D. The parties enter this agreement to govern the ongoing supply of pharmaceutical products in compliance with Cap. 244, WHO Good Distribution Practice (GDP) guidelines, the Anti-Counterfeit Act No. 13 of 2008, and all applicable PPB regulations.

Products, Ordering, and Delivery

1. PRODUCTS 1.1 The Supplier agrees to supply the following pharmaceutical products: [Description of Pharmaceutical Products] 1.2 All products shall be registered with the PPB. No unregistered product shall be supplied. 1.3 A current Product Schedule (Exhibit A) listing all products, PPB registration numbers, dosage forms, pack sizes, and storage conditions shall be maintained and updated by written agreement. 2. ORDERING AND DELIVERY 2.1 Minimum order per delivery: [Minimum Order Quantity / Value] 2.2 Delivery lead time: [Delivery Lead Time] 2.3 Delivery Terms: [Delivery Terms (Incoterms 2020)] (Incoterms 2020) 2.4 Each delivery shall include: delivery note, invoice, Certificate of Analysis (CoA), Certificate of Conformity (CoC), batch numbers, expiry dates, and (for cold chain products) temperature monitoring records. 2.5 Cold Chain: [Does Supply Include Cold Chain Products?] — where applicable, the Supplier shall comply with the PPB Cold Chain Management Guidelines and WHO GDP guidelines for temperature-sensitive pharmaceutical products.

Pricing and Payment

2. PRICING 2.1 [Pricing Structure] 2.2 The Supplier shall notify the Buyer at least 30 days before any price increase. 2.3 Resale Price Maintenance: The Supplier shall not fix the price at which the Buyer resells products to the public. Any such provision is void under Section 21 of the Competition Act No. 12 of 2010. 4. PAYMENT 4.1 Currency: [Currency of Payment] 4.2 Credit Period: [Credit Period] from invoice date 4.3 Payment Method: [Payment Method] 4.4 Late Payment Interest: [Late Payment Interest Rate] on overdue amounts from the due date until payment in full.

Quality Assurance and Recall

3. QUALITY ASSURANCE 3.1 [Quality Warranty] 3.2 The Buyer shall inspect deliveries within 48 hours of receipt. Written notice of any quality defect must be given within 5 business days with documentary evidence. 3.3 Quality disputes unresolved within 14 days shall be referred to an independent KEBS-accredited pharmaceutical testing laboratory for binding analysis. 6. PRODUCT RECALL 6.1 [Recall Procedure] 6.2 Both parties shall comply with PPB Product Recall Guidelines and Section 35A of Cap. 244. 7. ANTI-COUNTERFEITING 7.1 The Supplier warrants that all products carry authentication features required by the Anti-Counterfeit Act No. 13 of 2008. 7.2 The Buyer shall report any suspected counterfeit products immediately to the Anti-Counterfeit Authority (ACA) and the PPB.

Term, Termination, and Governing Law

4. TERM AND TERMINATION 4.1 This agreement commences on the date of execution and continues for [Initial Contract Term], thereafter renewing automatically for successive one-year terms unless terminated. 4.2 Either party may terminate on 30 days written notice. Rights and obligations already accrued are not affected. 4.3 This agreement terminates automatically if either party PPB licence is revoked, suspended, or not renewed. 9. DISPUTE RESOLUTION 9.1 The parties shall attempt resolution by good faith negotiation within 21 days of a written dispute notice. 9.2 If unresolved: [Dispute Resolution Mechanism] 10. GOVERNING LAW 10.1 This agreement is governed by the laws of Kenya, including the Pharmacy and Poisons Act Cap. 244, the Competition Act No. 12 of 2010, and the Anti-Counterfeit Act No. 13 of 2008. SIGNED BY THE PARTIES: For and on behalf of [Supplier Legal Name]: Signature: ________________________ Name: ________________________ Title: ________________________ Date: ________________________ For and on behalf of [Buyer Legal Name]: Signature: ________________________ Name: ________________________ Title: ________________________ Date: ________________________

Supplier Authorised Representative

________________

Signature

Buyer Authorised Representative

________________

Signature

What Is a Pharmaceutical Supply Agreement (Kenya)?

A Pharmaceutical Supply Agreement in Kenya sets out the rights, duties and consideration binding the parties to it.

The Pharmacy and Poisons Act Cap. 244 establishes the Pharmacy and Poisons Board (PPB) as the national regulatory authority for pharmaceutical products in Kenya. The PPB, operating under Part II of Cap. 244, is responsible for registering all pharmaceutical products for sale in Kenya (Section 35 of Cap. 244 prohibits sale of unregistered medicines), licensing pharmaceutical premises including manufacturing facilities, wholesale dealer premises, and retail pharmacies, and regulating the quality, safety, and efficacy of pharmaceutical products through post-market surveillance. As of 2024, the PPB has been reconstituted as the Kenya Pharmacy and Poisons Board under the Health Act No. 21 of 2017 and continues its regulatory functions.

All parties to a Pharmaceutical Supply Agreement in Kenya must hold valid licences from the PPB. A wholesale drug dealer's licence under Section 32 of Cap. 244 is required to operate a pharmaceutical wholesale business. A retail pharmacy licence (pharmacist's licence and premises registration certificate) is required to operate a retail pharmacy. A manufacturer's licence is required to manufacture pharmaceutical products. Import permits are required under Section 36 of Cap. 244 for each consignment of imported pharmaceutical products. The PPB register of licensed premises and registered products is published on the PPB website and must be checked before entering into a supply agreement.

Pharmaceutical Supply Agreements in Kenya must also comply with the Kenya Bureau of Standards (KEBS) standards for pharmaceutical products, the WHO Good Distribution Practices (GDP) guidelines incorporated by the PPB into its licensing requirements, and the Anti-Counterfeit Act No. 13 of 2008 administered by the Anti-Counterfeit Authority (ACA) — which requires product authentication systems to prevent distribution of counterfeit medicines. The Medical Practitioners and Dentists Board (MPDB) and the Nursing Council of Kenya (NCK) regulate prescribers and dispensers, while the PPB regulates the supply chain.

The supply of narcotic drugs and psychotropic substances in Kenya is subject to additional controls under the Narcotic Drugs and Psychotropic Substances (Control) Act No. 4 of 1994, which requires specific licences, record-keeping, and security measures beyond those in Cap. 244. Pharmaceutical Supply Agreements covering controlled substances must specifically address these additional regulatory requirements.

The legal framework governing the Pharmaceutical Supply Agreement (Kenya) in Kenya draws on several key statutes and regulatory bodies. Under the Companies Act No. 17 of 2015, the Registrar of Companies at the Office of the Attorney General maintains the register of Kenyan companies. Section 3 of the Law of Contract Act (Cap. 23) governs contractual obligations. The Competition Authority of Kenya (CAK) enforces the Competition Act No. 12 of 2010. The Kenya Revenue Authority (KRA) administers corporate tax under the Income Tax Act (Cap. 470). The High Court of Kenya has unlimited original jurisdiction under Article 165 of the Constitution of Kenya 2010. Parties executing a Pharmaceutical Supply Agreement (Kenya) in Kenya should confirm the document reflects current law, including any amendments enacted since the original drafting date. The Pharmacy and Poisons Act Cap. 244 sets the foundational requirements.

When Do You Need a Pharmaceutical Supply Agreement (Kenya)?

A Pharmaceutical Supply Agreement in Kenya under the Pharmacy and Poisons Act Cap. 244 is required in several common commercial situations involving the supply of pharmaceutical products.

A supply agreement is needed when a pharmaceutical wholesaler or distributor enters into a regular supply relationship with a retail pharmacy — community pharmacies, supermarket pharmacies, hospital out-patient pharmacies — to provide branded and generic medicines on ongoing credit terms. Without a formal supply agreement, the terms of supply, credit limits, return policies, and quality dispute resolution are undefined, leading to recurring commercial disputes.

A supply agreement is needed when a pharmaceutical manufacturer or importer engages a distribution partner to distribute its registered products through the Kenyan healthcare system. Kenya has a significant generic medicines manufacturing industry — including Universal Corporation Limited, Dawa Limited, Cosmos Limited, and Beta Healthcare International — and international pharmaceutical companies including GlaxoSmithKline Kenya, Reckitt Benckiser Kenya, and Sanofi Kenya distribute through licensed distributors under formal supply and distribution agreements.

A supply agreement is needed when a healthcare facility — public or faith-based hospital, Level 4 or Level 5 health facility, or private hospital — procures pharmaceutical products directly from a manufacturer or distributor rather than through the Kenya Medical Supplies Authority (KEMSA). Private hospitals including Aga Khan University Hospital, Nairobi Hospital, Mater Misericordiae Hospital, and MP Shah Hospital all maintain formal pharmaceutical supply agreements with multiple suppliers.

A supply agreement is needed when a county government pharmacy department or county health department establishes supply arrangements with pharmaceutical suppliers for medicines dispensed at county health facilities, complementing or supplementing supplies from KEMSA under the County Health System.

A supply agreement is also needed when a pharmaceutical company engages a cold chain logistics provider to distribute temperature-sensitive biological products — vaccines, insulin, biologics — that require specific storage and transport conditions under the PPB Cold Chain Management Guidelines.

Parties in Kenya should prepare a Pharmaceutical Supply Agreement (Kenya) proactively rather than waiting for a dispute to arise. Under the Companies Act No. 17 of 2015, the Registrar of Companies at the Office of the Attorney General maintains the register of Kenyan companies. Section 3 of the Law of Contract Act (Cap. 23) governs contractual obligations. The Competition Authority of Kenya (CAK) enforces the Competition Act No. 12 of 2010. The Kenya Revenue Authority (KRA) administers corporate tax under the Income Tax Act (Cap. 470). The High Court of Kenya has unlimited original jurisdiction under Article 165 of the Constitution of Kenya 2010.

What to Include in Your Pharmaceutical Supply Agreement (Kenya)

A Pharmaceutical Supply Agreement in Kenya under the Pharmacy and Poisons Act Cap. 244 must address the following critical elements to confirm regulatory compliance, commercial clarity, and product quality assurance.

Parties and Regulatory Credentials: Full legal names of the Supplier and Buyer, their physical and postal addresses, PPB licence numbers (wholesale dealer licence, retail pharmacy registration certificate, or facility registration number), and Kenya Revenue Authority (KRA) PIN numbers. The agreement should confirm that both parties hold valid, current PPB licences and that all products to be supplied are registered with the PPB under Section 35 of Cap. 244. If the Supplier is a foreign manufacturer, their authorised Kenya representative and import permit arrangements under Section 36 of Cap. 244 must be identified.

Product Schedule and Specifications: A detailed schedule of pharmaceutical products to be supplied — including international non-proprietary names (INN), brand names, PPB registration numbers, dosage forms, pack sizes, and applicable storage conditions (ambient, refrigerated, or frozen). The product schedule should reference the PPB registration certificate and the WHO International Nonproprietary Names (INN) list. Any changes to the product schedule — including new product registrations or deregistrations by the PPB — should trigger a contract amendment process.

Ordering and Delivery: Procedures for placing purchase orders, minimum order quantities, lead times, delivery locations, and delivery documentation (including delivery notes, certificates of analysis, batch numbers, expiry dates, and storage temperature records for cold chain products). Delivery terms should specify whether supply is on Ex Works (EXW), Cost Insurance and Freight (CIF), Delivered Duty Paid (DDP), or other Incoterms 2020 basis, particularly relevant for imported products cleared through the Kenya Ports Authority (KPA) at Mombasa.

Quality Assurance and Batch Documentation: Obligations for the Supplier to provide a Certificate of Analysis (CoA) and Certificate of Conformity (CoC) for each batch supplied, confirming compliance with PPB registration specifications and pharmacopoeial standards (British Pharmacopoeia, United States Pharmacopoeia, or WHO pharmacopoeia). The agreement should specify procedures for sampling, testing, and rejection of non-conforming batches, with reference to the PPB Good Distribution Practice (GDP) guidelines and the WHO GDP guidelines.

Pricing and Payment Terms: The agreed pricing structure — ex-factory price, distributor price, or pharmacy purchase price — and any applicable discounts, rebates, and promotional allowances. Payment terms should specify credit periods, acceptable payment instruments (M-Pesa merchant payment, RTGS via SWIFT, or cheque), late payment interest rates, and the currency of payment (KES or USD for imported products). The Kenya Competition Act No. 12 of 2010 prohibits resale price maintenance — provisions fixing the retail price at which the Buyer sells to end consumers are illegal.

Recall Procedures: A clear protocol for product recalls initiated by the PPB, the Supplier, or the Buyer following identification of quality, safety, or counterfeit concerns. The protocol should align with the PPB Product Recall Guidelines and specify notification timelines, quarantine procedures, return logistics, and financial responsibility for recall costs. Under Section 35A of Cap. 244 (as amended), both the Supplier and the Buyer have regulatory obligations to comply with PPB recall notices promptly.

Anti-Counterfeiting Compliance: Provisions requiring the Supplier to supply products with authentication features complying with the Anti-Counterfeit Act No. 13 of 2008 — including tax stamps, holograms, or digital authentication systems approved by the Anti-Counterfeit Authority (ACA) — and requiring the Buyer to report any suspected counterfeit products to the ACA and PPB.

The Pharmaceutical Supply Agreement Kenya template is a practical drafting framework for licensed pharmaceutical suppliers and buyers operating under the Pharmacy and Poisons Act Cap. 244.

Sources & Citations

Statutory citations link to the official government text where one is available, otherwise to a free law library named next to the link.

  1. Competition Act No. 12 of 2010KE official
  2. Law of Contract Act (Cap. 23)KE official
  3. Companies Act No. 17 of 2015KE official
  4. Income Tax Act (Cap. 470)KE official
  5. Health Act No. 21 of 2017KE official

Cite this page

CC BY 4.0 · free to cite

Reference this free template in an article, syllabus, or research note:

APA
Forms Legal. (2026). Pharmaceutical Supply Agreement (Kenya) [Legal document template]. Forms Legal. https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya
MLA
"Pharmaceutical Supply Agreement (Kenya)." Forms Legal, 2026, https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya.
Chicago
Forms Legal. "Pharmaceutical Supply Agreement (Kenya)." Forms Legal, 2026. https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya.
BibTeX
@misc{formslegal-pharmaceutical-supply-agreement-kenya,
  author       = {{Forms Legal}},
  title        = {Pharmaceutical Supply Agreement (Kenya)},
  year         = {2026},
  howpublished = {\url{https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya}},
  note         = {Free legal document template. Based on Pharmacy and Poisons Act Cap. 244}
}
Wikipedia
{{cite web |title=Pharmaceutical Supply Agreement (Kenya) |website=Forms Legal |publisher=Forms Legal |date=2026 |url=https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya}}
RIS
TY  - ELEC
T1  - Pharmaceutical Supply Agreement (Kenya)
T2  - Forms Legal
PB  - Forms Legal
PY  - 2026
UR  - https://forms-legal.com/kenya/business/contracts/pharmaceutical-supply-agreement-kenya
ER  - 
Forms Legal

Frequently Asked Questions

What licences are needed to supply medicines in Kenya?

The supply of pharmaceutical products in Kenya is licensed by the Pharmacy and Poisons Board (PPB) under the Pharmacy and Poisons Act Cap. 244. A wholesale drug dealer wishing to supply medicines to pharmacies, hospitals, and other authorised recipients must hold a valid wholesale drug dealer's licence issued by the PPB under Section 32 of Cap. 244. This licence is renewed annually and requires the wholesale dealer to maintain licensed premises meeting PPB GDP standards, employ a qualified superintendent pharmacist registered with the PPB, and maintain proper records of all transactions. A pharmaceutical manufacturer supplying its own products must hold a valid manufacturer's licence from the PPB under Section 29 of Cap. 244. An importer of foreign-manufactured pharmaceutical products must hold an import permit for each consignment under Section 36 of Cap. 244, in addition to the wholesale dealer's licence. The PPB publishes a register of licensed wholesale drug dealers on its website (ppb.go.ke), and parties entering into supply agreements should verify the current licence status of all suppliers and buyers. County governments procuring medicines for county health facilities may also work through the Kenya Medical Supplies Authority (KEMSA), which holds its own PPB licences and government procurement framework agreements.

Must all pharmaceutical products supplied in Kenya be registered with the PPB?

Yes. Section 35 of the Pharmacy and Poisons Act Cap. 244 prohibits any person from selling, supplying, or distributing a pharmaceutical product in Kenya unless the product is registered in the Kenya Register of Pharmaceutical Products maintained by the PPB. Registration by the PPB confirms that the product's quality, safety, and efficacy has been evaluated and that the product meets Kenya's regulatory standards. A PPB registration number (in the format KEN/EXP/NDA/XXX/XXXX) must appear on the product label of all registered pharmaceutical products in Kenya. Unregistered pharmaceutical products — including products imported without PPB registration, products awaiting registration, or products whose registration has lapsed — may not be legally supplied or sold in Kenya. The supply of unregistered pharmaceutical products is an offence under Cap. 244 attracting criminal penalties including fines and imprisonment. The PPB maintains an online register of all registered pharmaceutical products accessible through its website. Supplier parties to Pharmaceutical Supply Agreements in Kenya should warrant to the Buyer that all supplied products are registered with the PPB and that their registration will be maintained for the duration of the supply relationship.

How are pharmaceutical product quality disputes resolved in Kenya?

Quality disputes in pharmaceutical supply agreements in Kenya have both contractual and regulatory dimensions. At the contractual level, the Pharmaceutical Supply Agreement should include a clear product quality dispute resolution procedure: the Buyer gives written notice of the quality complaint within a specified time after delivery, attaches documentary evidence (inspection report, laboratory analysis from a KEBS-accredited laboratory), and the Supplier has a specified time to investigate and respond. If the Supplier accepts the complaint, the remedies include replacement of defective batches, credit notes, or refund. If the Supplier disputes the complaint, referral to an independent KEBS-accredited pharmaceutical laboratory for binding analysis is standard practice. At the regulatory level, the PPB has authority under Cap. 244 to investigate quality complaints, direct product recall, impose market suspension, and prosecute suppliers of substandard medicines under the PPB Pharmacovigilance and Post-Market Surveillance programme. Either party to a supply agreement can report a quality defect to the PPB, which triggers a separate regulatory investigation. The Kenya Bureau of Standards (KEBS) maintains a list of accredited pharmaceutical testing laboratories in Kenya. For high-value disputes not resolved through the contractual quality procedure, commercial arbitration at the Nairobi Centre for International Arbitration (NCIA) under Kenyan law is appropriate.

Are pharmaceutical supply agreements subject to competition law in Kenya?

Yes. Pharmaceutical Supply Agreements in Kenya are subject to the Competition Act No. 12 of 2010, administered by the Competition Authority of Kenya (CAK). Several provisions of pharmaceutical supply agreements can breach competition law. Resale price maintenance — a Supplier fixing the minimum or maximum price at which a Buyer (pharmacy) resells medicines to the public — is prohibited under Section 21 of the Competition Act as a restrictive trade practice. Exclusive dealing arrangements — requiring the Buyer to purchase exclusively from the Supplier and not from competing suppliers — may be prohibited under Section 23 if they have an anticompetitive effect on the relevant market. Tie-in arrangements — requiring the Buyer to purchase a second product as a condition of purchasing the desired product — are prohibited under Section 22 of the Competition Act. The CAK has been active in the pharmaceutical sector, noting the public health implications of anticompetitive practices in medicines supply. The Kenya Association of Pharmaceutical Manufacturers (KAPM) and the Kenya Pharmaceutical Association (KPA) provide guidance on competition-compliant supply terms. Pharmaceutical supply agreements should be reviewed to ensure that exclusive territory arrangements, minimum purchase commitments, and rebate structures do not cross the line into prohibited anticompetitive conduct under the Competition Act No. 12 of 2010.

What are the requirements for supplying cold chain pharmaceutical products in Kenya?

Cold chain pharmaceutical products — including vaccines, insulin, biologics, and other temperature-sensitive medicines — require strict temperature-controlled storage and distribution in Kenya, regulated by the PPB Cold Chain Management Guidelines and WHO Good Distribution Practices (GDP) for pharmaceutical products requiring temperature management. Suppliers of cold chain products must maintain licensed cold storage facilities with validated temperature ranges (typically 2°C to 8°C for refrigerated products, or -20°C to -15°C for frozen products), equipped with continuous temperature monitoring systems and temperature mapping data. Delivery vehicles must be validated cold chain transport units with data loggers recording temperature throughout the delivery journey. Temperature excursion protocols must be documented and tested — specifying what happens if temperature limits are breached during storage or transit, including product quarantine, investigation, and PPB notification. The Kenya Medical Supplies Authority (KEMSA) maintains the largest vaccine cold chain network in Kenya in partnership with UNICEF Kenya and the National Vaccines and Immunization Programme (NVIP) under the Ministry of Health. For private pharmaceutical supply agreements involving cold chain products, the agreement should incorporate by reference the WHO technical report series on cold chain management and specify acceptable temperature ranges, monitoring procedures, and liability allocation for temperature excursions.

Can foreign pharmaceutical companies supply medicines directly to pharmacies in Kenya?

Foreign pharmaceutical manufacturers cannot directly supply medicines to pharmacies or healthcare facilities in Kenya without complying with the Pharmacy and Poisons Act Cap. 244 licensing and registration requirements. A foreign manufacturer wishing to supply medicines in Kenya must: (1) register the product(s) with the PPB under Section 35 of Cap. 244, submitting a full dossier (CTD format) demonstrating quality, safety, and efficacy — registration typically takes 12-24 months; (2) appoint a local authorised agent who is a licensed wholesale drug dealer under Section 32 of Cap. 244 to act as the importer and distributor; (3) obtain import permits from the PPB under Section 36 of Cap. 244 for each consignment; and (4) comply with the Import Declaration Form (IDF) and Conformity Assessment Programme requirements of the Kenya Bureau of Standards (KEBS). The local authorised agent acts as the interface between the foreign manufacturer and the Kenya market and takes legal responsibility for the quality and regulatory compliance of imported products in Kenya. The Pharmaceutical Supply Agreement in Kenya is therefore typically between the local licensed distributor (as Supplier) and the pharmacy or healthcare facility (as Buyer), with the foreign manufacturer as a background party through a separate distribution or licence agreement. East African Community (EAC) mutual recognition arrangements for pharmaceutical product registration are progressively being implemented, which may simplify cross-border registration within the EAC partner states.

Based on Pharmacy and Poisons Act Cap. 244 — text last edited October 2026

This template is provided for informational purposes only and does not constitute legal advice. Laws vary by jurisdiction and change over time. Consult a qualified attorney for advice specific to your situation.Full disclaimer

Found an error? Let us know